According to Royalty Pharma's latest financial reports the company has $1.23 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $1.23 B | -49.18% |
2022-12-31 | $2.42 B | -13.39% |
2021-12-31 | $2.80 B | 5.82% |
2020-12-31 | $2.64 B | 233.97% |
2019-12-31 | $0.79 B | -66.76% |
2018-12-31 | $2.38 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $7.27 B | 489.99% | ๐บ๐ธ USA |
Eli Lilly LLY | $2.92 B | 137.30% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.22 B | -82.08% | ๐บ๐ธ USA |